The impact of FGFR1 and FRS2α expression on sorafenib treatment in metastatic renal cell carcinoma
about
Targeting of tumor growth and angiogenesis underlies the enhanced antitumor activity of lenvatinib in combination with everolimusKRT6 interacting with notch1 contributes to progression of renal cell carcinoma, and aliskiren inhibits renal carcinoma cell lines proliferation in vitro.FGFs: crucial factors that regulate tumour initiation and progression.Strategies to overcome therapeutic resistance in renal cell carcinoma.
P2860
The impact of FGFR1 and FRS2α expression on sorafenib treatment in metastatic renal cell carcinoma
description
2015 nî lūn-bûn
@nan
2015 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
The impact of FGFR1 and FRS2α ...... etastatic renal cell carcinoma
@ast
The impact of FGFR1 and FRS2α ...... etastatic renal cell carcinoma
@en
type
label
The impact of FGFR1 and FRS2α ...... etastatic renal cell carcinoma
@ast
The impact of FGFR1 and FRS2α ...... etastatic renal cell carcinoma
@en
prefLabel
The impact of FGFR1 and FRS2α ...... etastatic renal cell carcinoma
@ast
The impact of FGFR1 and FRS2α ...... etastatic renal cell carcinoma
@en
P2093
P2860
P1433
P1476
The impact of FGFR1 and FRS2α ...... etastatic renal cell carcinoma
@en
P2093
Carla L Warneke
Eric Jonasch
Marcella M Johnson
Pheroze Tamboli
Xian-De Liu
P2860
P2888
P356
10.1186/S12885-015-1302-1
P407
P577
2015-04-18T00:00:00Z
P5875
P6179
1039548874